GLENMARK LAUNCHES WINLEVI® IN KEY EUROPEAN MARKETS 🌍💊

• 🇪🇺 Glenmark has launched Winlevi® (clascoterone) 10 mg/g cream across key European markets for the treatment of acne vulgaris • 🧬 Marks Glenmark's first New Chemical Entity (NCE) launch in Europe • 🌎 Initial launches cover the Nordics, Central & Eastern Europe, Spain and Portugal, with further expansion planned • 🤝 Product is being commercialized in partnership with Cosmo/Cassiopea • 👩‍⚕️ Winlevi® is approved in the EU for treating acne vulgaris in adults and adolescents • 🔬 Clascoterone is the first commercially available topical androgen-receptor inhibitor for acne treatment • 📈 Launch strengthens Glenmark's dermatology portfolio and branded business presence in Europe • 🎯 Expands access to differentiated therapies and supports Glenmark's innovation-led growth strategy 🟢 Impact: Positive (Enhances Glenmark's specialty dermatology portfolio, marks a significant innovation milestone in Europe and opens a new growth avenue for branded products.)

KEY CORP LTD.

← Back to feed